OK-101 achieves dry eye disease sign, symptom endpoints in phase 2 trial

Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.
“It is remarkable that in this first-in-human study of OK-101 ophthalmic solution, an analysis of all randomized subjects demonstrated a persistent, statistically significant improvement in multiple dry eye-related symptoms as early as day 15, along with a sign, total conjunctival lissamine green staining, by day 29,” Jay Pepose, MD, PhD, founder and

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart